Corgenix Medical Corp. Announces Launch of Products for Automated Systems

DENVER, March 2 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

The new format offers high-volume testing labs the same performance as the currently available Corgenix rapid assay with improved efficiency and high-volume analysis.

"Offering both extended and short assay formats allows us to maintain our leadership position in anti-phospholipid antibody detection," said Douglass Simpson, Corgenix CEO and President. "Our customers can now compete more effectively with enhanced automated performance."

Automated microplate ELISA processing from Corgenix is available for a wide range of anti-phospholipid antibody screening tests, including anti-Cardiolipin (aCL) antibodies, anti-Phosphatidylserine (aPS) antibodies and anti-Beta2 Glycoprotein I IgG antibodies.

As the first company to obtain FDA clearance of its anti-Cardiolipin test, Corgenix maintains its commitment to offer the highest quality tests associated with SLE (lupus) and antiphospholipid syndrome, autoimmune mediated thrombotic diseases. It is estimated that over 3 million individuals in the United States and 10 million worldwide have lupus or lupus-like disorders.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED